Core Insights - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following disappointing financial results and issues with internal controls [1][3]. Company Overview - Simulations Plus is a software company specializing in modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2]. Acquisition Details - In June 2024, Simulations Plus acquired Pro-ficiency Holdings, Inc., aiming to double its total addressable market and enhance sales [2][3]. Financial Performance and Stock Impact - On April 15, 2025, Simulations Plus hired Grant Thornton LLP as its new auditor, which was followed by a significant stock price drop after the company announced disappointing preliminary financial results for Q3 2025 on June 11, 2025, with a decline of over 24% from $26.44 to $20.05 per share [4]. - The company reported a $77.2 million charge related to prior acquisitions in its Q3 2025 financial results on July 14, 2025, and subsequently dismissed Grant Thornton, citing unresolved matters regarding segment reporting and internal controls [5]. Auditor Dispute - Grant Thornton disagreed with Simulations Plus's characterizations regarding internal controls and reporting, leading to further stock price decline of nearly 26% from $17.47 to $12.97 per share following the announcement of the impairment charge and auditor findings [5].
SLP STOCK NOTICE: Simulations Plus, Inc. Investors with Losses may have been Affected by Securities Fraud – Contact BFA Law about its Pending Investigation